After previously deciding against endorsing weight-loss drugs to treat obesity in 2023, the World Health Organization (WHO) has reversed its position and now supports the use of GLP-1s for weight loss.

This shift reflects growing recognition of the clinical effectiveness of GLP-1 medications in treating obesity. At the same time, it raises questions around long-term affordability and global access—especially in lower-income regions.

The WHO is currently developing guidelines for the use of GLP-1s in weight management and is expected to release formal treatment recommendations by fall 2025. The organization is also considering adding medications like semaglutide to its Essential Medicines List, which could help make these treatments more accessible across a broader population.

Why this matters: 

The WHO’s new position reinforces what many healthcare providers have already seen—GLP-1s are an effective tool for weight loss. It also highlights the urgent need for more affordable, accessible options, particularly as demand grows. At Shed, that’s exactly what we’re working to provide.

We’re committed to making evidence-based treatments like GLP-1s available through a personalized, affordable care model. These medications, while not appropriate for everyone, can be a powerful part of a comprehensive weight-loss plan when used under the guidance of a licensed medical provider.

With insurance acceptance right around the corner, we will continue to make both GLP-1s and additional weight-loss treatments available to anyone seeking help on their weight-loss journey.

Read the full Reuters article here.